MTOR and neoplasm: Tumor heterogeneity in humans impacts the immunoexpression of proteins in the mTOR pathway in PC, and the decrease in mTOR immunoexpression is considered a late event after tumor progression, being associated with worse clinical and oncological outcomes in patients [105].